CD38 and Miyoshi myopathy: For patients newly diagnosed with MM who cannot undergo autologous HSCT, the primary initial therapy options are RD (lenalidomide and dexamethasone), bortezomib-based regimens (RVD), or anti-CD38-based regimens (Dara-Rd), or modified dosing of Dara-RVD.